RxDoctor Payments Data

Melecia Fuentes, MD

Family Medicine · Donna, TXNPI 1083713952

Payments from drug & device makers

$6,489in general payments, 2019–2025

Across 373 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$906
  • Amgen$633
  • Abbott$586
  • Bayer$541
  • AstraZeneca$519
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$6,45099%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,489 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,151
Medicare patients
118
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin150$209,775
OzempicSemaglutide122$154,513
ProliaDenosumab90$141,992
RybelsusSemaglutide67$141,169
MounjaroTirzepatide121$133,814
XareltoRivaroxaban70$101,775
EliquisApixaban46$68,750
KerendiaFinerenone39$47,736
Icosapent Ethyl78$39,321
Repatha SureclickEvolocumab56$39,034
Nurtec OdtRimegepant Sulfate19$29,955
LinzessLinaclotide19$22,641
TrulicityDulaglutide13$21,837
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,557
Synjardy XrEmpagliflozin/Metformin Hcl11$13,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,378$295,682189 claims
Boehringer IngelheimJardiance, Synjardy Xr$63$223,598161 claims
Lilly USA, LLCMounjaro, Trulicity$906$155,651134 claims
AmgenProlia$633$141,99290 claims
Johnson & JohnsonXarelto$184$101,77570 claims
PfizerEliquis, Nurtec Odt$203$98,70565 claims
BayerKerendia$541$47,73639 claims
AbbVieLinzess$276$22,64119 claims
GSKTrelegy Ellipta, Breo Ellipta$19$20,68529 claims
MerckLagevrio (Eua)$115$11,90914 claims
Kowa Pharmaceuticals America, Inc.Livalo$57$5,83613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Donna

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →